News

AI generates proteins with exceptional binding strength

Ian C. Haydon
By Ian C. Haydon
Feb. 3, 2024

A new study in Nature reports an AI-driven advance in biotechnology with implications for drug development, disease detection, and environmental monitoring. Scientists at the Institute for Protein Design at the University of Washington School of Medicine used software to create protein molecules that bind with exceptionally high affinity and specificity to a variety of challenging biomarkers, including human hormones. Notably, the scientists achieved the highest interaction strength ever reported between a computer-generated biomolecule and its target.

Susana Vasquez-Torres in a UW Medicine Institute for Protein Design laboratory, where she is working to develop new proteins with high-binding affinity and specificity to a variety of challenging biomarkers.
Ian Haydon, UW Medicine Institute for Protein Design
Susana Vasquez-Torres in a UW Medicine Institute for Protein Design laboratory, where she is working to develop new proteins with high-binding affinity and specificity to a variety of challenging biomarkers.

Senior author David Baker, professor of biochemistry at UW Medicine, Howard Hughes Medical Institute investigator, and recipient of the 2023 Frontiers of Knowledge Award in Biology and Biomedicine, emphasized the potential impact: "The ability to generate novel proteins with such high binding affinity and specificity opens up a world of possibilities, from new disease treatments to advanced diagnostics."

A new protein designed using deep-learning methods. In this case, RFdiffusion generates a binding protein.
Ian Haydon/UW Medicine Institute for Protein Design
A new protein designed using deep-learning methods. In this case, RFdiffusion generates a binding protein.

The team, led by Baker Lab members Susana Vazquez-Torres, Preetham Venkatesh, and Phil Leung, set out to create proteins that could bind to glucagon, neuropeptide Y, parathyroid hormone, and other helical peptide targets. Such molecules, crucial in biological systems, are especially difficult for drugs and diagnostic tools to recognize because they often lack stable molecular structures. Antibodies can be used to detect some of these medically relevant targets but are often costly to produce and have limited shelf lives.

"There are many diseases that are difficult to treat today simply because it is so challenging to detect certain molecules in the body. As tools for diagnosis, designed proteins may offer a more cost-effective alternative to antibodies," explained Venkatesh.

The study introduces a novel protein design approach that uses advanced deep-learning methods. The researchers present a new way of using RFdiffusion, a generative model for creating new protein shapes, in conjunction with the sequence-design tool ProteinMPNN. Developed in the Baker Lab, these programs allow scientists to create functional proteins more efficiently than ever before. By combining these tools in new ways, the team generated binding proteins by using limited target information, such as a peptide's amino acid sequence alone. The broad implications of this  "build to fit" approach suggest a new era in biotechnology in which AI-generated proteins can be used to detect complex molecules relevant to human health and the environment.

An AI-designed protein in detail from the UW Medicine Institute for Protein Design.
Ian Haydon/UW Medicine Institute for Protein Design
An AI-designed protein in detail from the UW Medicine Institute for Protein Design.

"We're witnessing an exciting era in protein design, where advanced artificial intelligence tools, like the ones featured in our study, are accelerating the improvement of protein activity. This breakthrough is set to redefine the landscape of biotechnology," noted Vazquez-Torres.

In collaboration with the Joseph Rogers Lab at the University of Copenhagen and the  Andrew Hoofnagle Lab at UW Medicine, the team conducted laboratory tests to validate their biodesign methods. Mass spectrometry was used to detect designed proteins that bind to low-concentration peptides in human serum, thereby demonstrating the potential for sensitive and accurate disease diagnostics. Additionally, the proteins were found to retain their target binding abilities despite harsh conditions including high heat, a crucial attribute for real-world application. Further showcasing the method's potential, the researchers integrated a high-affinity parathyroid hormone binder into a biosensor system and achieved a 21-fold increase in bioluminescence signal in samples that contained the target hormone. This integration into a diagnostic device highlights the immediate practical applications of AI-generated proteins.

The study, which illustrates the confluence of biotechnology and artificial intelligence and sets a new precedent in both fields, appears in Nature with the title “De novo design of high-affinity binders of bioactive helical peptides.”

(This article was produced by the University of Washington School of Medicine/UW Medicine.)

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ian C. Haydon
Ian C. Haydon

Ian C. Haydon is a science communicator and head of communications at the Institute for Protein Design, University of Washington School of Medicine. He holds a master's degree in biochemistry and was a 2018 Mass Media Fellow with the American Association for the Advancement of Science. He specializes in making biotechnology make sense.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.